Kymera Therapeutics (KYMR) Expected to Announce Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Kymera Therapeutics to post earnings of ($0.77) per share and revenue of $14.81 million for the quarter.

Kymera Therapeutics Stock Up 1.4 %

NASDAQ KYMR opened at $37.65 on Thursday. The company has a 50-day simple moving average of $39.97 and a two-hundred day simple moving average of $44.09. Kymera Therapeutics has a 12-month low of $29.24 and a 12-month high of $53.27. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -16.09 and a beta of 2.18.

Insider Buying and Selling

In related news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares of the company’s stock, valued at $2,288,985.50. This represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 15.82% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Morgan Stanley upped their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Guggenheim upped their price target on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Truist Financial restated a “buy” rating and set a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Stephens restated an “overweight” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, UBS Group dropped their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a report on Monday, November 4th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $55.06.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.